Results 161 to 170 of about 62,474 (297)

The results of aflibercept therapy as a first line treatment of age-related macular degeneration

open access: yesJournal of Current Ophthalmology, 2019
Purpose: To report the results of aflibercept treatment in treatment-naive neovascular age-related macular degeneration (AMD) patients and suggest a suitable treatment algorithm for routine clinical practice.
Erkan Unsal, Mehmet Ozgur Cubuk
doaj  

Perception and Localization of Macular Degeneration Applying Convolutional Neural Network, ResNet and Grad-CAM [PDF]

open access: yesarXiv
A well-known retinal disease that sends blurry visions to the affected patients is Macular Degeneration. This research is based on classifying the healthy and macular degeneration fundus by localizing the affected region of the fundus. A CNN architecture and CNN with ResNet architecture (ResNet50, ResNet50v2, ResNet101, ResNet101v2, ResNet152 ...
arxiv  

Alleles in the HtrA Serine Peptidase 1 Gene Alter the Risk of Neovascular Age-Related Macular Degeneration [PDF]

open access: green, 2008
Margaret M. DeAngelis   +10 more
openalex   +1 more source

HYAMD High-Resolution Fundus Image Dataset for age related macular degeneration (AMD) Diagnosis [PDF]

open access: yesarXiv
The Hillel Yaffe Age Related Macular Degeneration (HYAMD) dataset is a longitudinal collection of 1,560 Digital Fundus Images (DFIs) from 325 patients examined at the Hillel Yaffe Medical Center (Hadera, Israel) between 2021 and 2024. The dataset includes an AMD cohort of 147 patients (aged 54-94) with varying stages of AMD and a control group of 190 ...
arxiv  

Long term visual and microperimetry outcomes following autologous retinal pigment epithelium choroid graft for neovascular age-related macular degeneration [PDF]

open access: green, 2008
Fred K. Chen   +7 more
openalex   +1 more source

How to treat recurrences after Avastin treatment for neovascular AMD: stick to Avastin or switch to Lucentis? [PDF]

open access: yes, 2008
Haritoglou, Christos   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy